Drug response,
written in the genome.
We profile and elucidate the relationships between human genomes, haplotypes, and drug responses — turning genetic diversity into safer, more precise prescribing.
Haplotype-resolved pharmacogenomics
A population-scale atlas linking phased haplotypes to drug-metabolism phenotypes across diverse ancestries — capturing compound and population-specific effects that single-variant analyses miss.
Predicting adverse drug response
Interpretable machine-learning models that combine genome, haplotype, and clinical features to estimate individual risk of adverse drug reactions before a prescription is written.
Tools for precision prescribing
Open software — adeRisk and personPsyMatch — that turns a pharmacogenomic profile into actionable, individualized prescribing guidance, with the genetic evidence surfaced rather than hidden.
adeRisk
2025adeRisk scans an individual’s single-nucleotide variants across pharmacogenes andknown adverse-event loci, then stratifies a cohort into risk groups for a givendrug. It combines curated star-allele definitions with variant-level effectweights to estimate the probability that a patient falls into a high-risk groupfor a specific adverse drug reaction, producing a ranked report that cliniciansand researchers can act on.
personPsyMatch
2024personPsyMatch matches a patient’s pharmacogenomic profile againstmetabolizer-phenotype models for commonly prescribed psychoactive medications andreturns a ranked, individualized list of candidate drugs and dose considerations.Built as a decision-support aid for precision psychiatry, it surfaces the geneticevidence behind each recommendation rather than issuing a single opaque answer.
Impact of CYP2C:TG Haplotype on CYP2C19 Substrates Clearance In Vivo, Protein Content, and In Vitro Activity
Zubiaur P, Soria-Chacartegui P, Boone EC, et al.
link DOI